Please assess the completion status of the following clinical trial:

Trial Title: High Dose vs. Standard Influenza Vaccine in Adult SOT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Organ transplant recipient on at least one immunosuppressive~* Age \>=18~* Outpatient status~* Greater than 3 months post transplant~Exclusion Criteria:~* Has already received influenza vaccination for 2016-2017 season~* Egg allergy or allergy to previous influenza vaccine~* Febrile illness in the past one week~* Active Cytomegalovirus viremia~* Use of Rituximab in the past 6 months~* Ongoing or recent (in past 30 days) therapy for acute rejection~* Chronic kidney insufficiency (creatinine clearance ≤30mL/min or dialysis-dependent~* Previous life-threatening reaction to influenza vaccine (i.e. Guillain Barre Syndrome)~* Receipt of intravenous immunoglobulin (IVIG) in the past 30 days or planning to receive IVIG in the next 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluzone High-dose Influenza Vaccine (Type: EXPERIMENTAL): This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
- Standard 2016-2017 Flu vaccine (Type: ACTIVE_COMPARATOR): This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).